• Corporate
• Markets
• Info-Tech
• Marketing
• Money & Banking
• Agri-Biz & Commodities
• Industry & Economy
• Logistics
• Government
• Opinion
• Corporate Results
• Columns
• States
• Web Extras
• Index

• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

• Rates

• Ports

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Subscription

• Business Line

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

MUMBAI: Drug firm Piramal Life Sciences on Tuesday reported a net loss of Rs 28.12 crore for the June quarter ended current fiscal as compared to Rs 21.27 crore in the same period last year.

Net sales rose to Rs 1.73 crore for quarter ended June 30, 2009 against Rs one lakh in the same period ended June 2008, Piramal Life Sciences said in a filing to the Bombay Stock Exchange (BSE).

Last year, drug firm Piramal Healthcare had changed the name of its research and development centre to Piramal Life Sciences from NPIL Research and Development.

Shares of Piramal Life Sciences hit upper limit at Rs 60.10 on the BSE, up 9.97 per cent from previous close. – PTI

Prev: ABB bags Rs 141-cr order
Next: HEC making operational profits since 2006-07: Minister

Copyright copy; 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line